On April 10, 2021, the first SAIF Banker Practice Course of the year, themed Healthcare: Biopharmaceuticals, was successfully held at the Xuhui Campus of Shanghai Jiao Tong University. Mr. Mao Hua, Partner and Managing Director of Frost & Sullivan's Greater China region, was invited to participate in the roundtable discussion session focusing on the development and investment opportunities of the biopharmaceutical industry.
SAIF Banker Live Broadcast
Special Session on Biomedicine in the Healthcare Big Health Series
The global outbreak of the COVID-19 pandemic has made biomedicine, especially the field of innovative drug research and development, a focal point of attention for all sectors. Although the market share of domestic innovative drugs is still relatively small at this stage, with the government gradually introducing policies to support the development of domestic innovative drugs and the continuous increase in R&D investment by pharmaceutical companies, a large number of local innovative biopharmaceutical enterprises have emerged. The innovative development of China's biopharmaceutical industry will accelerate. At the same time, due to the characteristics of the biopharmaceutical industry such as high innovation costs, significant investment risks, and long R&D cycles, capital has also become an indispensable force in helping biopharmaceutical enterprises develop.
Against this backdrop, the first lecture of SAIF Banker's Practice Course focuses on the biopharmaceutical industry. It invites several experts from academia and industry to gain insights into industry trends from different perspectives, analyze industry policies, and discuss future investment opportunities.
Professor Wang Honglin delivered a keynote speech
Professor Wang Honglin, a doctoral supervisor at the School of Medicine of Shanghai Jiao Tong University, a specially-appointed professor at Shanghai Jiao Tong University, the director of the Translational Medicine Center at Shanghai First People's Hospital, and an outstanding academic leader in Shanghai, delivered a keynote speech titled 'The Journey of New Drug R&D with Independent Intellectual Property Rights'.
Professor Wang Honglin has presided over several national-level research projects, including a key research and development project funded by the Ministry of Science and Technology as the chief scientist, and has received the National Science Fund for Distinguished Young Scholars. He has made a series of innovative research achievements in the fields of skin immune diseases, skin stem cell biology, and basic and translational medicine research on psoriasis. In his keynote speech, Professor Wang combined his many years of research experience to use the development process of a small molecule innovative drug for psoriasis treatment as an example. From perspectives such as "the value and significance of choosing psoriasis as the research direction for new drugs," "the operation mode of the human immune system," "the relationship between the nervous system and diseases," and "the definition and current status of First-in-Class in new drug research," he explained in simple terms to the audience present the process of domestic innovative drug research and exploration.
The roundtable discussion focused on the development and practice of biopharmaceutical investment in China. Professor Jiang Zhan, a professor at Shanghai Advanced Finance Institute, academic director and executive director of the EED project, Mr. Mao Hua, partner and managing director of Frost & Sullivan Greater China, Mr. Xiao Li, an alumnus of the Gaojin Finance MBA program and executive director of Honghui Capital, as well as Professor Wang Honglin participated in the discussion. Mr. Yang Shujun, vice president of Junlian Capital, presided over the roundtable session.
After a brief self-introduction, the guests present engaged in an in-depth discussion based on their years of experience and research, starting with topics such as 'changes in the biopharmaceutical industry over the past five to ten years', 'future IPOs and mergers and acquisitions trends in the healthcare sector', and other related issues. They took into account aspects such as talent in the pharmaceutical industry, scientific research environment, market demand, top-level design of industrial policies, capital markets, and the impact brought about by COVID-19. They also answered questions from the audience present.
Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China Region
Professor Jiang Zhan, Professor at Shanghai Advanced Finance Institute, Academic Director and Executive Director of the EED Project
Xiao Li, Executive Director of Honghui Capital and Alumni of SAIF Financial MBA
Yang Shujun, Vice President of Junlian Capital
